Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PulmatrixPULM +0.64%30 EV-to-FCF is 0.80 as of Jul. 16, 2026. GuruFocus rates PULM with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 334 Biotechnology companies, Pulmatrix ranks better than 79.34% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pulmatrix's Enterprise Value is $-3.75 Mil.
Pulmatrix's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.69 Mil. Therefore, Pulmatrix's EV-to-FCF for today is 0.80.
The historical rank and industry rank for Pulmatrix's EV-to-FCF or its related term are showing as below:
PULM'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.66 Med: -0.38 Max: 3.53
Current: 0.8
During the past 13 years, the highest EV-to-FCF of Pulmatrix was 3.53. The lowest was -5.66. And the median was -0.38.
PULM's EV-to-FCF is ranked better than 79.34% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs PULM: 0.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pulmatrix's share price for today is $1.58.
Pulmatrix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pulmatrix EV-to-FCF Related Terms
Pulmatrix EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pulmatrix's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pulmatrix's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmatrix EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulmatrix's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pulmatrix's EV-to-FCF falls into.
Pulmatrix's current Enterprise Value is $-3.75 Mil.
Pulmatrix's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmatrix (PULM) has a EV-to-FCF of 0.80 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pulmatrix and its competitors. According to the industry distribution chart, Pulmatrix ranks #69 out of 334 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Pulmatrix's EV-to-FCF too high?
Pulmatrix's current EV-to-FCF is 0.80. The Biotechnology industry median EV-to-FCF is 15.69. Pulmatrix's value of 0.80 is 94.9% below this industry median. Based on the distribution chart, Pulmatrix ranks #69 out of 334 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pulmatrix has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Pulmatrix's EV-to-FCF compare to CDIO and NXTC?
According to the Biotechnology industry distribution chart, Pulmatrix ranks #69 out of 334 companies for EV-to-FCF. This places Pulmatrix in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.69. Pulmatrix's value of 0.80 is 94.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulmatrix's current EV-to-FCF of 0.80 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pulmatrix and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulmatrix's current EV-to-FCF is 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmatrix stock overvalued right now?
Pulmatrix (PULM) has a current EV-to-FCF of 0.80. The current EV-to-FCF is 0.80 and 94.9% below the Biotechnology industry median of 15.69. Pulmatrix's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pulmatrix (PULM), the current EV-to-FCF is 0.80 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
30GF Score
Get the complete analysis for PULM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PULM has been successfully added to your 
